Metastatic cancer cells circulate through every organ via blood vessels, and can infiltrate some more than others to eventually cause lethal pathological dysfunction. Metastasis to distant organs, including liver, brain and the skeleton is nowadays the main cause of death in patients treated for breast or prostate cancer. Metastasis to the skeleton is very common, as 73% of patients with terminal breast and prostate cancers have evidence of metastatic bone disease [@bib1], [@bib2]. This leads to predominantly lytic lesions causing pain, hypercalcemia, fractures, and spinal cord/nerve compression. Metastasis may remain confined to the skeleton, and eventual cause of mortality is almost entirely due to skeletal complications and their treatments. The 5-year survival rate of women diagnosed with bone metastasis is 22% (National Cancer Institute\'s SEER database).

There are multiple reasons why the skeleton is a preferential organ for metastasis. First, it is a large and well-vascularized tissue, with a fenestrated sinusoidal vasculature that may favor circulating cancer cell arrest and establishment into the skeleton, especially for cancer cells metastasizing as cluster. Host cells residing within the bone marrow environment also secrete a number of cytokines and extracellular matrix proteins that promote the homing or retention of metastatic cancer cells within the skeleton, as well as their survival, dormancy and drug resistance [@bib3].

Skeletal metastasis in women with advanced breast cancer often leads to death within a couple of years. Though the above mentioned skeletal complications and their treatment contribute to this high mortality rate, additional mechanisms are likely to be involved. The fact that the skeleton is an endocrine organ that can impact the function of other organs, including the pancreas [@bib4], [@bib5], the gonads [@bib6] and muscles [@bib7] for instance suggests that skeletal metastasis, especially at late stages, can disrupt general body homeostasis, thereby leading to the morbidities afflicting relapsing patients. Because of the irreversible and complex nature of late stage disease, earlier detection of metastatic events is likely to result in higher treatment efficacy and to increase the survival of these patients. Thus, characterizing the early determinants of skeletal metastasis is necessary to uncover novel targets and strategies to eradicate metastatic cells at early stages.

Studies focused on the early determinants of skeletal metastasis are difficult for many reasons, including challenges in detecting, tracing, and studying small numbers of metastatic cells within the skeleton and the lack of good preclinical models of early bone metastasis. One strategy to progress in this area, however, is to search for specific conditions that can favor skeletal metastasis or tumor recurrence in patients with metastatic cancers. Answers to this question could lead to the discovery of specific target(s) that could be used to prevent or limit skeletal metastasis, or to increase the exposure of metastatic cells to cytotoxic drugs.

Chronic stress and depression are prevalent in individuals with low socioeconomic status. These conditions are associated with higher cancer recurrence and reduced survival in women with breast cancer [@bib8], [@bib9], [@bib10], [@bib11], [@bib12], [@bib13], [@bib14], and also share the common activation of a defense mechanism characterized by the release of catecholamines by sympathetic nerves and glucocorticoids by the adrenal glands. This is an adaptive and physiological response to acute stress, which can become pathological in the setting of chronic stress, depression, and other traumatic emotional events that trigger prolonged sympathetic nervous system (SNS) and hypothalamic-pituitary-adrenal (HPA) axis activation. What links these observations to the bone marrow environment and bone metastasis is that sympathetic nerves richly innervate the skeleton and release norepinephrine (NE) as a neuromediator to regulate bone remodeling and bone homeostasis [@bib15]. Specifically, osteoblasts express the β2-adrenergic receptor (β2AR), and its stimulation by NE leads to the synthesis of RANKL, a well-known osteoclastogenic cytokines with promigratory properties toward cancer cells [@bib16], [@bib17], [@bib18], [@bib19]. Other studies also revealed that the mobilization of hematopoietic stem cell from the bone marrow environment into the blood circulation was under the control of sympathetic signals and SDF1/CXCL12, a cytokine also involved in the homing of metastatic cells into the skeleton [@bib20]. These observations thus suggested that psychosocial factors known to induce SNS and HPA chronic activation impact the bone marrow environment to transform it into a "fertile soil" favoring cancer cell metastasis.

To experimentally address this hypothesis, one first needs models of bone metastasis. The intracardiac injection model of cancer cells allows the investigation of metastatic events ulterior to growth and egress from the primary tumor. One also needs mouse models of depression or chronic stress, which are associated with SNS and HPA activation. These models are numerous and can be classified based on exposure and response to various types of acute or chronic stressors. Learned helplessness, chronic mild stress, or social defeat stress are widely used mouse models of depression and stress. A pharmacologic alternative to these models is the use of βAR agonists such as isoproterenol (Iso), which simulates SNS activation specifically, although it should be noted that the duration and intensity of the Iso signal may differ from the endogenous βAR ligands NE and epinephrine because of endogenous release kinetics and differences in metabolism. These tools allowed independent groups to provide experimental evidence supporting the hypothesis that sympathetic activation induced by chronic stress or severe depression favors metastasis to soft organs and bones. Using intracardiac injections of osteotropic MDA-MD-231 and 4T1 breast cancer cells, and a mouse model of learned helplessness (chronic immobilization stress, CIS), we have shown that SNS activation for two weeks prior to cancer cell inoculation increases the number of metastatic foci into the skeleton as well as bone destruction [@bib21]. In addition, blockade of SNS action on target tissues by the β-blocker propranolol inhibits this CIS stimulatory effect on bone metastasis, suggesting that sympathetic activation and the βAR in osteoblasts mediate this pathological response to emotional stimuli [@bib21].

The results of additional experiments suggested that the pro-migratory properties of RANKL mediate this effect of CIS on the host bone marrow environment and breast cancer cell bone metastasis. Indeed, βAR stimulation in osteoblasts leads to a strong increase in RANKL expression, and the conditioned medium of these cells could stimulate breast cancer cell migration *in vitro*. This could be inhibited by OPG, the RANKL decoy receptor. Most importantly, knock down of the RANKL receptor RANK in MDA-MD-231 bone metastatic breast cancer cells reduced the effect of CIS on bone metastasis *in vivo* [@bib21]. These data thus suggested that sympathetic activation via an indirect effect on the bone stroma, and specifically via NE and the βAR expressed in bone cells, promotes breast cancer cell engraftment within the bone marrow in a RANKL-dependent fashion ([Fig. 1](#f0005){ref-type="fig"}). The existence of RANK-negative cells in bone metastatic tumors, however, suggests that additional mechanisms exist [@bib22]. In addition, a direct effect of NE on cancer cells is suspected (most of these cells express the βARs). Studies using ovarian cancer cells for instance indicated that CIS/SNS activation promotes the growth and invasion properties of these tumors [@bib23], [@bib24], [@bib25]. There is also evidence that sympathetic activation in the primary tumor causes remodeling of the host stroma, leading to an environment that is favorable for cancer cell egress and dissemination to distant organs [@bib26]. The contribution of sympathetic and parasympathetic nerves to the skeletal metastasis and growth of prostate cancer cells has also been demonstrated in animal models [@bib27]. Taken together, these studies provide experimental evidence for a significant contribution of the sympathetic nervous system to priming the bone microenvironment for cancer metastasis.

These studies in mice suggest that interventions aimed at reducing sympathetic activation, βAR signaling, or RANKL expression or signaling might limit breast cancer cell metastatic engraftment in the skeleton and improve the prognosis of women with early breast cancer diagnosis. This is supported by several clinical studies. Longer disease-free survival [@bib28] and lower metastasis development and tumor recurrence were observed in women on β-blockers [@bib29], [@bib30]. Another study reported less advanced disease at diagnosis and lower cancer-specific mortality in patients who had taken propranolol 1 year before diagnosis [@bib31], thus the use of β-blockers at early stage of the disease seems to be critical to observe a protective effect on mortality [@bib32], [@bib33], [@bib34]. A beneficial effect of β-blockers on patient survival was detected for other types of cancer than breast cancer, including ovarian cancer [@bib35], and RANKL blockade increased metastasis-free survival in men with castration-resistant prostate cancer [@bib36]. In conclusion, both clinical association data and preclinical data in mice support a stimulatory role of the sympathetic nervous system in the skeletal establishment of metastatic cancer cells, which appears relevant to a number of solid and possibly blood cancers.

**Outstanding questions:**•Does β2AR stimulation in breast cancer cells, in addition to osteoblastic β2AR stimulation, contribute to their engraftment into the skeleton?•Do skeletal sympathetic nerves contribute in establishing a "fertile soil" in bone via host β2AR-expressing osteoblasts only, or via other cells such as immune or endothelial cells known to be responsive to sympathetic signals?•Does the increase in glucocorticoids induced by HPA activation in response to chronic stress contributes to the observed effect of SNS activation on breast cancer cell metastasis to the skeleton?•Do β-blockers or RANKL blockade improve patient survival by reducing skeletal metastasis or by limiting early metastatic growth?•Although high RANK levels in primary breast cancer tumors are predictive of bone metastasis and worst prognosis, the mechanism by which RANK-negative breast cancer cells metastasize into the skeleton is unknown.
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